pepsico
Key Points Shares of PepsiCo are near all-time highs, outperforming competitors while still paying a hefty dividend yield.APAC CEO points to the company’s presence in the region being positioned to ride building tailwinds. These macro indicators indicate he is pretty close.Investors will find that this segment, depending on a Chinese plant, could be the key to unlocking a new rally, blowing past analyst expectations.5 stocks we like better than PepsiCoShares of PepsiCo (NASDAQ:PEP) are hovering near their all-time high prices of $195.50, as the company experienced bullish momentum in fundament...
ValueWalk
PepsiCo Inc. beat on the top and bottom line and guided favorably as well.The analyst sentiment has slipped but the price target is on the way up.The dividend will help support the prices, which increased by 10%.5 stocks we like better than PepsiCoThe price action in PepsiCo Inc. (NASDAQ:PEP) pulled back from a high recently, but this weakness in the action offers a buying opportunity in a Dividend King. PepsiCo’s Q4 results prove the company’s strategy continues to work and has what it takes to succeed in today’s market: brand strength and pricing power. Q4 2022 hedge fund letters, conference...
ValueWalk
Pepsico pays a market-beating dividend and provides some safety from broad-market volatility.The company beat its Q3 consensus expectation and guided the market higher.Long-term trends suggest growth, capital returns, and dividend growth will continue in calendar 2023.Pepsico (NASDAQ:PEP) has been lagging behind the broad market since the pandemic bottom but that may be about to change. The company’s performance may be tied to its high valuation, it trades near 24X earnings, but the valuation is well earned and the stock has many attractive qualities for investors. Q3 2022 hedge fund letters, ...
ValueWalk
PepsiCo Inc (NASDAQ:PEP) topped analysts’ expectations in terms of third-quarter earnings, with the company raising its full-year estimates despite supply chain and inflation. Pepsi stock edged below 1% on Tuesday. Q2 2021 hedge fund letters, conferences and more Earnings ReportAs informed by CNBC, supply chain disruptions, and inflationary pressures for labor, commodities, and transportation were all computed in the company’s fiscal results for the quarter. In terms of earnings per share, the company topped $1.79 against a $1.73 estimate. Likewise, the company reported a revenue of $20.19 bil...
ValueWalk
PepsiCo, Inc. (NASDAQ:PEP) has reported organic revenue growth of 13% to $19.2bn, with underlying operating profit up 22% to $3.2bn. This reflects strong performances from all divisions apart from Quaker Foods North America, and there was particularly strong growth in PepsiCo Beverages North America. Q2 2021 hedge fund letters, conferences and more PepsiCo Expects FY Organic Revenue Growth Of 6%Management has increased guidance. They now expect full year organic revenue growth of 6%, compared to mid-single-digits, and an 11% increase in underlying earnings per share, compared to high single di...
ValueWalk
Beyond Meat has teamed up with PepsiCo to create a line of plant-based beverages and snacks. The joint venture between the two companies will be called the PLANeT Partnership, and it will be formed as a limited liability corporation. Q4 2020 hedge fund letters, conferences and more Beyond Meat and PepsiCo announce joint ventureAccording to CNBC, the joint venture between Beyond Meat and PepsiCo will enable Beyond to leverage Pepsi's production and marketing expertise for new products. Beyond Meat is a relative newcomer to the market. "PepsiCo represents the ideal partner for us in this excitin...
ValueWalk
2021 may feel more like an extension of 2020 rather than a fresh start. But take heart-there is plenty of good news out there. Q4 2020 hedge fund letters, conferences and more Here are four things to be hopeful about today: Weapons Against The CoronavirusFirst, we now have weapons against the coronavirus. The US has two approved vaccines. England, China and Russia have developed their own. Additional vaccines are under development and will likely be available later this year. These will be game-changers if we manage to deploy them widely and quickly. Which, I admit, is a big “if.” The initial ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら